208 related articles for article (PubMed ID: 28178664)
1. Identification of distinct molecular subtypes of uterine carcinosarcoma.
An Y; Wang H; Jie J; Tang Y; Zhang W; Ji S; Guo X
Oncotarget; 2017 Feb; 8(9):15878-15886. PubMed ID: 28178664
[TBL] [Abstract][Full Text] [Related]
2. OSucs: An Online Prognostic Biomarker Analysis Tool for Uterine Carcinosarcoma.
An Y; Wang Q; Sun F; Zhang G; Wang F; Zhang L; Li Y; Ren W; Zhu W; Li Y; Ji S; Guo X
Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32899312
[TBL] [Abstract][Full Text] [Related]
3. Molecular classification and subtype-specific drug sensitivity research of uterine carcinosarcoma under multi-omics framework.
Lu X; Zhang L; Zhao H; Chen C; Wang Y; Liu S; Lin X; Wang Y; Zhang Q; Lu T; Yan F
Cancer Biol Ther; 2019; 20(2):227-235. PubMed ID: 30359167
[TBL] [Abstract][Full Text] [Related]
4. Uterine carcinosarcoma: A review of the literature.
Cantrell LA; Blank SV; Duska LR
Gynecol Oncol; 2015 Jun; 137(3):581-8. PubMed ID: 25805398
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
6. Uterine carcinosarcomas: From pathology to practice.
Toboni MD; Crane EK; Brown J; Shushkevich A; Chiang S; Slomovitz BM; Levine DA; Dowdy SC; Klopp A; Powell MA; Thaker PH
Gynecol Oncol; 2021 Jul; 162(1):235-241. PubMed ID: 34030871
[TBL] [Abstract][Full Text] [Related]
7. Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma.
Li J; Xing X; Li D; Zhang B; Mutch DG; Hagemann IS; Wang T
Neoplasia; 2017 Feb; 19(2):100-111. PubMed ID: 28088687
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and status of hormone receptors and angiogenic factors in uterine carcinosarcoma.
Etoh T; Nakai H
J Obstet Gynaecol Res; 2014 Mar; 40(3):820-5. PubMed ID: 24320058
[TBL] [Abstract][Full Text] [Related]
9. Executive summary of the American Radium Society® Appropriate Use Criteria for management of uterine carcinosarcoma.
Elshaikh MA; Modh A; Jhingran A; Biagioli MC; Coleman RL; Gaffney DK; Harkenrider MM; Heskett K; Jolly S; Kidd E; Lee LJ; Li L; Portelance L; Sherertz T; Venkatessan AM; Wahl AO; Yashar CM; Small W
Gynecol Oncol; 2020 Aug; 158(2):460-466. PubMed ID: 32475772
[TBL] [Abstract][Full Text] [Related]
10. Uterine and Ovarian Carcinosarcomas: Do They Behave Similarly?
Ureyen I; Karalok A; Cirik DA; Tasci T; Gokce ZK; Duzguner IB; Tulunay G; Turan T
J Obstet Gynaecol Can; 2017 Jul; 39(7):559-563. PubMed ID: 28625283
[TBL] [Abstract][Full Text] [Related]
11. RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma.
Mi S; Lin M; Brouwer-Visser J; Heim J; Smotkin D; Hebert T; Gunter MJ; Goldberg GL; Zheng D; Huang GS
Clin Cancer Res; 2016 Sep; 22(18):4676-86. PubMed ID: 27121792
[TBL] [Abstract][Full Text] [Related]
12. HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line.
Stockhammer P; Okumus Ö; Hegedus L; Rittler D; Ploenes T; Herold T; Kalbourtzis S; Bankfalvi A; Sucker A; Kimmig R; Aigner C; Hegedus B
Pathol Oncol Res; 2021; 27():636088. PubMed ID: 34257602
[No Abstract] [Full Text] [Related]
13. Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Saito A; Nishikawa T; Yoshida H; Mizoguchi C; Kitadai R; Yamamoto K; Yazaki S; Kojima Y; Ishikawa M; Kato T; Yonemori K
Gynecol Oncol; 2023 Sep; 176():115-121. PubMed ID: 37506533
[TBL] [Abstract][Full Text] [Related]
14. Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival.
Rojas C; Tian C; Powell MA; Chan JK; Bateman NW; Conrads TP; Rocconi RP; Jones NL; Shriver CD; Hamilton CA; Maxwell GL; Casablanca Y; Darcy KM
Gynecol Oncol; 2020 Apr; 157(1):67-77. PubMed ID: 32029291
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical Markers With Potential Diagnostic, Prognostic, and Therapeutic Significance in Uterine Carcinosarcoma: A Clinicopathologic Study of 43 Cases.
Jones TE; Pradhan D; Dabbs DJ; Bhargava R; Onisko A; Jones MW
Int J Gynecol Pathol; 2021 Jan; 40(1):84-93. PubMed ID: 31855950
[TBL] [Abstract][Full Text] [Related]
16. Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: A systematic review and meta-analysis of survival.
Raffone A; Travaglino A; Raimondo D; Maletta M; De Vivo V; Visiello U; Casadio P; Seracchioli R; Zullo F; Insabato L; Mollo A
Int J Gynaecol Obstet; 2022 Sep; 158(3):520-527. PubMed ID: 34797919
[TBL] [Abstract][Full Text] [Related]
17. Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.
Liu Y; Weber Z; San Lucas FA; Deshpande A; Jakubek YA; Sulaiman R; Fagerness M; Flier N; Sulaiman J; Davis CM; Fowler J; Starks D; Rojas-Espaillat L; Lazar AJ; Davies GE; Ehli EA; Scheet P
Gynecol Oncol; 2018 Nov; 151(2):243-249. PubMed ID: 30194005
[TBL] [Abstract][Full Text] [Related]
18. AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma.
Saglam O; Husain S; Toruner G
Int J Gynecol Pathol; 2013 Sep; 32(5):493-500. PubMed ID: 23896716
[TBL] [Abstract][Full Text] [Related]
19. Uterine carcinosarcoma: a primer for radiologists.
Ravishankar P; Smith DA; Avril S; Kikano E; Ramaiya NH
Abdom Radiol (NY); 2019 Aug; 44(8):2874-2885. PubMed ID: 31030248
[TBL] [Abstract][Full Text] [Related]
20. Trends of uterine carcinosarcoma in the United States.
Matsuo K; Ross MS; Machida H; Blake EA; Roman LD
J Gynecol Oncol; 2018 Mar; 29(2):e22. PubMed ID: 29400015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
